EXOSC8 Antibody (N-term)
- Known as:
- EXOSC8 Antibody (N-terminus)
- Catalog number:
- AP2783a
- Category:
- -
- Supplier:
- Abgen
- Gene target:
- EXOSC8 Antibody (N-term)
Related genes to: EXOSC8 Antibody (N-term)
- Gene:
- EXOSC8 NIH gene
- Name:
- exosome component 8
- Previous symbol:
- -
- Synonyms:
- OIP2, RRP43, bA421P11.3, Rrp43p, EAP2, p9, CIP3
- Chromosome:
- 13q13.3
- Locus Type:
- gene with protein product
- Date approved:
- 2004-03-26
- Date modifiied:
- 2016-10-05
Related products to: EXOSC8 Antibody (N-term)
Related articles to: EXOSC8 Antibody (N-term)
- The RNA exosome complex (EXOSC1-10) orchestrates 3-5 RNA processing and decay, yet its family-wide landscape and clinical relevance in lung adenocarcinoma (LUAD) remain incompletely defined. Here, we conducted an integrative multi-omics analysis of EXOSC family members in LUAD using public transcriptomic and proteomic resources, external validation cohorts, and single-cell data. Across TCGA (59 normal vs. 515 tumors), all EXOSC genes were significantly upregulated in tumors, with concordant increases for most proteins in CPTAC and immunohistochemistry evidence from the Human Protein Atlas. Survival analyses identified EXOSC2, EXOSC3 and EXOSC5 as prognostically informative, with elevated EXOSC2/EXOSC5 also associated with inferior disease-specific survival. Receiver operating characteristic analyses indicated moderate-to-high diagnostic performance for several EXOSC genes, supported by qRT-PCR validation in LUAD cell lines and confirmation in GSE31210. Clinicopathological correlations linked EXOSC1-5 and EXOSC8-10 to advanced stage and metastatic features, whereas EXOSC6 and EXOSC7 showed comparatively limited or context-dependent associations, suggesting functional heterogeneity within the family. Genomic profiling revealed recurrent alterations in 11.83% of patients, with EXOSC4 exhibiting the highest alteration frequency (predominantly amplifications), and network analyses identified core interacting partners centered on RNA surveillance machinery. EXOSC expression was broadly correlated with RNA modification regulators (mA/mC/mA) and displayed heterogeneous relationships with immune checkpoint genes and immune infiltration, while higher EXOSC expression consistently associated with lower ESTIMATE-derived microenvironment scores and an immune profile characterized by Th2/T helper enrichment with reduced cytotoxic and antigen-presenting populations. Gene set enrichment analyses implicated cell-cycle regulation, senescence, chromatin-related programs and extracellular matrix pathways, and EXOSC-high tumors were associated with increased tumor mutational burden and homologous recombination deficiency, together with enrichment of DNA damage response pathways. Single-cell analysis (GSE146100) localized highest EXOSC expression to proliferating monocytes/macrophages and suggested TGF-β-linked communication with endothelial and T-cell compartments. Exploratory translational analyses further indicated an association between EXOSC9 and predicted cisplatin sensitivity. Collectively, these findings position the EXOSC family as a clinically and biologically relevant axis in LUAD, linking RNA surveillance dysregulation to immune contexture and genomic instability, and highlight subunit-specific heterogeneity that warrants mechanistic validation. - Source: PubMed
Publication date: 2026/05/22
Li NingWang XiaoleiChu TingtingPan YongxinZhang Xuezhong - In recent years, liquid-liquid phase separation (LLPS) has garnered increasing attention in the field of oncology. However, its role in osteosarcoma remains largely unexplored. We aimed to construct a prognostic risk model associated with LLPS and to investigate the impact of LLPS-related genes on osteosarcoma briefly. - Source: PubMed
Publication date: 2025/12/29
Huang XinyuXiong LiangZeng JiaxingLi ShanhangCai YangjieZou ZhuanYang MingxiuLi HeningLiu YunHe Maolin - Head and neck paragangliomas (HNPGLs) are rare neuroendocrine tumors that originate in the parasympathetic paraganglia of the head and neck. The diagnosis of these tumors is challenging, and the therapeutic options are limited. The study of HNPGLs is fraught with challenges at every stage. One of the main problems is the absence of HNPGL cell lines in cell repositories, which is associated with the difficulty of their culturing and low division rate. In this regard, neither functional nor preclinical studies are available for this category of tumors. This significantly slows down the study of the molecular mechanisms of HNPGL pathogenesis and the development of effective therapeutic approaches. Here, we investigated the molecular genetic characteristics of the primary HNPGL culture. Using the single-cell RNA sequencing method, expression patterns were analyzed, and cell types were annotated. The results demonstrated that the HNPGL primary culture cells were optimally divided into three clusters and had different degrees of differentiation, expressing neural tissue cell and stem cell markers. Exome sequencing revealed genetic abnormalities in the HNPGL culture, including mutations in the IGSF3, DHH, EXOSC8, SERPINA1, TYR, and NQO1 genes, aneuploidy, as well as multiple chromosomal duplications and deletions. These results enhance our knowledge of the molecular genetic features of successfully cultured HNPGL tumor cells. - Source: PubMed
Snezhkina A VFedorova M SPavlov V SPudova E AKatunina I VKalinin D VKobelyatskaya A AKudryavtseva A V - - Source: PubMed
Publication date: 2025/10/09
Sharifi ShahrashoubHeidargholizadeh G SomayyehNazemi AliÖzcan ÖzdenSahin AylaPalanduz ŞükrüŞentürk Leyli - Head and neck squamous cell carcinoma (HNSC) is a highly aggressive malignancy with poor prognosis, necessitating the identification of novel biomarkers for improved diagnosis and treatment. The exosome complex (EXOSC) family plays a crucial role in RNA metabolism, but its significance in HNSC remains poorly understood. We performed a comprehensive multi-omics analysis integrating data from TCGA, GEO, CPTAC, and the Human Protein Atlas to investigate the expression, prognostic value, and immune relevance of EXOSC genes in HNSC. We conducted differential expression analysis, survival analysis (OS, DSS, PFI), ROC curve evaluation, and clinicopathological correlation studies. Genetic alterations were examined using cBioPortal. Gene co-expression and enrichment analyses were used to elucidate potential molecular functions, and a protein-protein interaction (PPI) network was constructed via GeneMANIA. Immune infiltration, immune checkpoint correlations, and RNA modification associations were assessed using ssGSEA, Spearman correlation, and RNA modification databases. Experimental validation was performed by qRT-PCR in HNSC and normal cell lines. All EXOSC family members were significantly upregulated in HNSC tissues and cell lines. ROC analysis demonstrated favorable diagnostic potential, particularly for EXOSC2 (AUC = 0.910). Elevated expression of EXOSC2, EXOSC3, EXOSC8, and EXOSC9 was significantly associated with poor OS, DSS, and PFI. High expression of EXOSC2, EXOSC4, EXOSC5, and EXOSC9 correlated with advanced clinical stage, lymphovascular invasion, and poor therapeutic outcomes. cBioPortal analysis revealed EXOSC4 had the highest genetic alteration frequency (8%), primarily due to amplification. Immune infiltration analysis showed EXOSC gene expression was significantly correlated with various immune cell populations and immune checkpoint molecules, especially EXOSC3, EXOSC9, and EXOSC10. Functional enrichment and PPI network analyses indicated that EXOSC family genes participate in RNA metabolism, exoribonuclease activity, and immune-related pathways. A prognostic risk model based on EXOSC co-expressed genes demonstrated strong predictive performance for patient survival. Our study reveals that EXOSC family genes are significantly dysregulated in HNSC and are associated with tumor progression, prognosis, immune microenvironment modulation, and RNA modification. These findings highlight the potential of EXOSC members as novel diagnostic and prognostic biomarkers and suggest their relevance as therapeutic targets in HNSC. - Source: PubMed
Publication date: 2025/08/19
Zhang XuezhongZhao MengmengChu TingtingWei JiashaJia Qingmei